|
2004 Archive |
|
|
|
|
|
Biotech Monthly newsletters |
|
| December
2004 -
32
pgs. Main Story: Trends in Targeted Therapies |
|
|
|
| November
2004 -
64
pgs. Main Story: Dendreon (DNDN) |
|
|
|
| October
2004 -
32
pgs. Main Story: BioMarin Pharmaceuticals
(BMRN) |
|
|
|
| September
2004 -
34
pgs. Main Story: Corcept Therapeutics
(CORT) |
|
|
|
| August 2004 -
150
pgs.
Biotech Monthly Third Annual
Anniversary Issue |
|
| If you are
interested in biotech, you cannot miss this issue. 150 pages
detailing the outlook for all 21 companies in our
coverage universe. Our most popular issue and considered by some to
be the "handbook" for biotech investing for the second half of
the year. Also available for
single-issue purchase. |
|
|
|
| July 2004 -
29
pgs. Main Story: Valentis
(VLTS) |
|
|
|
| June 2004 -
48
pgs. Main Story: Oncologists "discover" targeted therapy |
|
|
|
| May 2004 -
15
pgs. Main Story: Genta (GNTA) |
|
|
|
| April 2004 -
23
pgs. Main Story: Dendritic cell therapies - Part 2 |
|
|
|
| March 2004 -
31
pgs. Main Story: Dendritic cell therapies |
|
|
|
| February 2004 -
25
pgs. Main Story: Forbes Medi-Tech (FMTI) |
|
|
|
| January 2004 -
29
pgs. Main Story: ODAC panel sends strong signal to investors |
|
|
|
| BSR
Alerts |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
